Leflunomidă Arena (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for de novo pyrimidine synthesis. By limiting pyrimidine production, it suppresses the proliferation of activated lymphocytes, thereby dampening the immune‑mediated inflammation that drives arthritis.

The specific dose and dosing schedule for Leflunomidă Arena are determined by the prescribing physician based on the patient’s clinical condition, disease severity, and laboratory monitoring. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Leflunomidă Arena is classified as pregnancy category X because it is known to cause fetal malformations. It should not be used by pregnant women, and effective contraception is required during treatment and for a defined period after discontinuation. Safety during breastfeeding has not been established, so it is generally avoided.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Leflunomidă Arena offers oral administration and a distinct mechanism— inhibition of pyrimidine synthesis—compared with biologic DMARDs that target cytokines or cell surface receptors. It may be chosen when patients prefer oral therapy or when biologics are contraindicated, but safety monitoring differs.

Store Leflunomidă Arena at room temperature below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Leflunomidă Arena is taken orally, usually as a tablet, with or without food as directed by the prescriber. Patients should swallow the tablet whole and avoid crushing or chewing unless specifically instructed.

The most serious risks include hepatotoxicity, severe infections due to immunosuppression, pulmonary toxicity, bone‑marrow suppression, and teratogenic effects. Regular laboratory monitoring and patient education are essential to detect these complications early.

Leflunomidă Arena should not be used by pregnant women, individuals with pre‑existing severe liver disease, uncontrolled hypertension, active infections, or those who are unable to use effective contraception. Contra‑indications are determined by the prescribing clinician.